Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 50K, Primers for KIT gene mutation testing.
Authors: Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Diaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark H. Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poire, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab L. Atallah, Philip Dy, Sachdev P. Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362394863